{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T15:54:48Z","timestamp":1769874888601,"version":"3.49.0"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.jneuroim.2015.05.012","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T22:06:11Z","timestamp":1431641171000},"page":"13-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Safety and efficacy of reduced fingolimod dosage treatment"],"prefix":"10.1016","volume":"285","author":[{"given":"Bassem I.","family":"Yamout","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3405-8967","authenticated-orcid":false,"given":"Maya M.","family":"Zeineddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja A.","family":"Sawaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia J.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2015.05.012_bb0005","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2015.05.012_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/11596550-000000000-00000","article-title":"Clinical pharmacokinetics of fingolimod","volume":"51","author":"David","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jneuroim.2015.05.012_bb0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2015.05.012_bb0020","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.jneuroim.2015.05.012_bb0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMct1101691","article-title":"Fingolimod for multiple sclerosis","volume":"366","author":"Pelletier","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2015.05.012_bb0030","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1177\/1352458512472750","article-title":"Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia","volume":"19","author":"Tanak","year":"2013","journal-title":"Mult. Scler. J."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815001241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815001241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:24:53Z","timestamp":1759047893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572815001241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":6,"alternative-id":["S0165572815001241"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.05.012","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of reduced fingolimod dosage treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}